Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)

Gynecologic Oncology

Volumn 137, Issue 2, 2015, Pages 229-238

  Pearl, Michael L ^a   Dong, Huan ^a,b   Tulley, Shaun ^a,b   Zhao, Qiang ^a,b   Golightly, Marc ^c   Zucker, Stanley ^a,d   Chen, Wen Tien ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Vitatex Inc   (United States)

^c Stony Brook School of Dental Medicine   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cell invasion; Circulating cancer cells; CTC; Metastasis detection; Ovarian cancer; Treatment monitoring

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; ENZYME ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MESSENGER RNA; PACLITAXEL; SEPRASE; CD44 PROTEIN, HUMAN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; SEPRASE, HUMAN; SERINE PROTEINASE; TUMOR MARKER;

ABDOMINAL DISEASE; ADULT; ANTIBODY LABELING; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; INVASIVE CIRCULATING TUMOR CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; ENVIRONMENTAL MONITORING; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM; TUMOR RECURRENCE;

ANTIGENS, CD44; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CASE-CONTROL STUDIES; COHORT STUDIES; ENVIRONMENTAL MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84933277202     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.03.002     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30.
2. Bast Jr RC, Klug TL, St JE, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
3. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA- 125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8.
4. Rustin GJ, Quinn M, Thigpen T, du BA, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
5. Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007;104:176-80.
6. van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol 2010;119:265-9.
7. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, et al. Exploratory analysis of serumCA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol 2009;115:209-14.
8. Swisher EM, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst 2012;104: 642-5.
9. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014;14:623-31.
10. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med 2014;7:1-11.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
12. Romero-Laorden N, Olmos D, Fehm T, Garcia-Donas J, Diaz-Padilla I. Circulating and disseminated tumor cells in ovarian cancer: a systematic review. Gynecol Oncol 2014;133:632-9.
13. Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol 2013;131:352-6.
14. Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 2011;122:567-72.
15. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
16. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008;26:1208-15.
17. Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2010;126:669-83.
18. Fan T, Zhao Q, Chen JJ, Chen W-T, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009;112:185-91.
19. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 2009;277:164-73.
20. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014;134:2284-93.
21. Pearl ML, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol 2014;134:581-90.
22. Kennedy A, Dong H, Chen D, Chen W-T. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer 2009;124:27-35.
23. Hailpern SM, Visintainer PF. Odds ratios and logistic regression: further examples of their use and interpretation. Stata J 2003;3:213-25.
24. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
25. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
26. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125: 437-46.
27. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171:386-95.
28. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2009;115:1028-35.
29. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
30. Chen W-T, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003;22:259-69.
31. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13:1736-41.
32. Tulley S, Chen W-T. Transcriptional regulation of seprase in invasive melanoma cells by transforming growth factor-beta signaling. J Biol Chem 2014;289:15280-96.
33. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, et al. Activation of EDTAresistant gelatinases in malignant human tumors. Cancer Res 2006;66:9977-85.
34. Levy T, Weiser R, Boaz M, Shem EB, Golan A, Menczer J. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response. Int J Gynecol Cancer 2012;22:1344-8.
35. Cochran WG. Sampling techniques. New York: John Wiley & Sons; 1977.
36. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011;130:449-55.
37. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant Gepar Quattro trial. Clin Cancer Res 2010;16:2634-45.
38. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
39. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 2000;19:219-301.
40. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998;44:1379-80.